患有型肝炎的无症状老年人的认知表现:教育的作用
Max Kopti Fakoury1,2,3,4, Sergio Luis Schmidt2,3,4, Carlos Eduardo Brandão Mello1,2,5
1Department of Internal Medicine, Gaffrée and Guinle University Hospital, Federal University of the State of Rio de Janeiro, Rio de Janeiro 21941-853, Brazil.
Journal of clinical medicine
|July 29, 2023
概括
与对照组相比,感染C型肝炎病毒 (HCV) 的老年人没有表现出认知障碍. 然而,高等教育显著改善了认知测试的表现,特别是HCV携带者的时钟绘图测试.
科学领域:
- 神经科学是一个神经科学.
- 肝病学 肝病学是一种肝病学.
- 老年病的医生 老年病的医生
背景情况:
- 型肝炎病毒 (HCV) 神经变可能导致微妙的神经心理症状.
- 年龄和HCV是认知障碍 (CI) 的潜在危险因素.
- 教育水平可以影响认知测试结果.
研究的目的:
- 为了比较老年HCV携带者与对照者的认知表现.
- 评估教育对这些群体认知功能的影响.
- 为了确定教育对认知的影响是否在HCV携带者和对照者之间有所不同.
主要方法:
- 对41名无症状的老年HCV携带者和41名对照者 (年龄大于60岁) 的匹配队列研究.
- 认知评估包括迷你Cog,迷你精神状态检查,时钟绘图测试 (CDT) 和口头流利.
- 统计分析探讨了群体差异和教育的影响.
主要成果:
- 在HCV携带者和对照者之间没有观察到显著的认知表现差异.
- 在所有参与者中,更高的教育成就始终与更好的认知表现相关.
- 在时钟绘图测试中发现了显著的相互作用,在此测试中,增加的教育显示了与对照组相比,HCV携带者在性能上有更大的改善.
结论:
- 与对照人群相比,老年HCV携带者没有表现出认知缺陷.
- 教育对认知功能有积极的影响,随着教育水平的提高,对HCV携带者的时钟绘图测试的影响更为明显.
相关概念视频
Cognitive Development During Adulthood
158
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
158
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
Esophageal Varices-II: Clinical Features and Management
96
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
96
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155
Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12


